Evidence map›Paper›PMID 26614754›Full record

ArticleBrain : a journal of neurology2016

Delayed intramuscular human neurotrophin-3 improves recovery in adult and elderly rats after stroke.

Denise A Duricki, Thomas H Hutson, Claudia Kathe, Sara Soleman, Daniel Gonzalez-Carter, Jeffrey C Petruska, H David Shine, Qin Chen, Tobias C Wood, Michel Bernanos and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain : a journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. [Experimental study of lentivirus-mediated Nogo extracellular peptide residues 1-40 gene and neurotrophin 3 gene co-transduction in neural stem cells].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2018
    Article
  20. The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments).Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Denise A Duricki1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 2 Centre for Integrative Biology, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK.
Thomas H Hutson1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 3 Division of Brain Sciences, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK.
Claudia Kathe1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK.
Sara Soleman1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 4 John Van Geest Centre for Brain Repair University of Cambridge, The E.D. Adrian Building, Forvie Site, Robinson Way Cambridge, CB2 0PY, UK.
Daniel Gonzalez-Carter1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 3 Division of Brain Sciences, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK.
Jeffrey C Petruska5 Department of Anatomical Sciences and Neurobiology, University of Louisville; Kentucky Spinal Cord Injury Research Center, Department of Neurological Surgery, Louisville, Kentucky, USA.
H David Shine6 Center for Cell and Gene Therapy, Department of Neuroscience, Alkek Bldg N1130.01, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.
Qin Chen6 Center for Cell and Gene Therapy, Department of Neuroscience, Alkek Bldg N1130.01, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.
Tobias C Wood7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK.
Michel Bernanos7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK.
Diana Cash7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK.
Steven C R Williams7 Neuroimaging Research Group, King's College London, PO42 De Crespigny Park, London, SE5 8AF, UK.
Fred H Gage8 The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA.
Lawrence D F Moon1 Neurorestoration Group, Wolfson Centre for Age-Related Diseases, King's College London, 16-18 Newcomen Street, London SE1 1UL, UK 2 Centre for Integrative Biology, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK lawrence.moon@kcl.ac.uk.
King's College London · GBBaylor College of Medicine · USHammersmith Hospital · GBNeurological Surgery · USSalk Institute for Biological Studies · USUniversity of Cambridge · GB

Funding

Arthritis Research UKChief Scientist OfficeEuropean Research Council 309731Medical Research Council G0600998
6 · The paper itself

Abstract

There is an urgent need for a therapy that reverses disability after stroke when initiated in a time frame suitable for the majority of new victims. We show here that intramuscular delivery of neurotrophin-3 (NT3, encoded by NTF3) can induce sensorimotor recovery when treatment is initiated 24 h after stroke. Specifically, in two randomized, blinded preclinical trials, we show improved sensory and locomotor function in adult (6 months) and elderly (18 months) rats treated 24 h following cortical ischaemic stroke with human NT3 delivered using a clinically approved serotype of adeno-associated viral vector (AAV1). Importantly, AAV1-hNT3 was given in a clinically-feasible timeframe using a straightforward, targeted route (injections into disabled forelimb muscles). Magnetic resonance imaging and histology showed that recovery was not due to neuroprotection, as expected given the delayed treatment. Rather, treatment caused corticospinal axons from the less affected hemisphere to sprout in the spinal cord. This treatment is the first gene therapy that reverses disability after stroke when administered intramuscularly in an elderly body. Importantly, phase I and II clinical trials by others show that repeated, peripherally administered high doses of recombinant NT3 are safe and well tolerated in humans with other conditions. This paves the way for NT3 as a therapy for stroke.

Indexed as

AdenoviridaeAge FactorsAnimalsEndothelin-1FemaleGenetic VectorsHumansInjections, IntramuscularLocomotionMagnetic Resonance ImagingMicroinjectionsMuscle, SkeletalNeuroimagingNeurotrophin 3Pyramidal TractsRatsEndothelin-1Neurotrophin 3corticospinalneurotrophin-3plasticitysproutingstroke

Identifiers

PMID26614754
PMCPMC4785394
OpenAlexW2178937067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.